摘要
目的探讨丁螺环酮合并利培酮对精神分裂症患者的疗效。方法选取244例住院精神分裂症患者随机分为丁螺环酮合并利培酮组(研究组)和单用利培酮组(对照组),治疗8周。治疗前后采用阳性和阴性综合征量表(PANSS)评估精神分裂症患者的临床疗效,采用精神分裂症认知功能成套测验共识版(MCCB)评估精神分裂症患者的认知功能。结果治疗后两组患者PANSS总分及各分量表分均较各自治疗前下降(P<0.05)。治疗后研究组PANSS总分、阴性分量表分低于对照组(P<0.05)。治疗后两组患者的MCCB总分及各维度分均较治疗前升高(P<0.05)。治疗后研究组连线错误数得分低于对照组(P<0.05),言语记忆分高于对照组(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论丁螺环酮合并利培酮较单用利培酮可更加有效改善精神精神分裂症患者的阴性症状及认知损害,具有增效作用。
Objective To explore efficacy of buspirone combined with risperidone to treat patients with schizophrenia.Methods A total of 244 patients with schizophrenia were randomly divided into study group with buspirone combined with risperidone and control group with risperidone for 8 weeks of treatment. They were assessed with Positive and Negative Syndrome Scale（ PANSS） and MATRICS Consensus Cognitive Battery（ MCCB） before and after treatment. Results In both groups,the total score and all factor scores of PANSS after treatment were all significantly lower than those before treatment（ P〈0. 05）.After treatment,the total score and negative factor score of PANSS in study group were all significantly lower than those in control group（ P〈0. 05）. In both groups,the total score and all factor scores of MCCB after treatment were all significantly higher than those before treatment（ P〈0. 05）. After treatment,the connection error number of MCCB in study group was significantly lower than that in control group（ P〈0. 05） and the verbal memory score of MCCB in study group was significantly higher than that in control group（ P〈0. 05）. There were no differences for incidence rate of side effects between both groups（ P〉0. 05）.Conclusion It ＇s effective for buspirone combined with risperidone to improve the negative symptoms and impairment of cognitive function in patients with schizophrenia.
出处
《精神医学杂志》
2017年第2期111-114,共4页
Journal of Psychiatry
关键词
精神分裂症
丁螺环酮
阴性症状
认知功能
Schizophrenia
Buspirone
Negative symptoms
Cognitive function
